Precision BioSciences (DTIL)
(Delayed Data from NSDQ)
$8.83 USD
+0.22 (2.56%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $8.71 -0.12 (-1.36%) 5:48 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
DTIL 8.83 +0.22(2.56%)
Will DTIL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DTIL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DTIL
Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
DTIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
Intra-Cellular (ITCI) Moves 23.3% Higher: Will This Strength Last?
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
Other News for DTIL
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
Precision BioSciences partner gets FDA clearance for Azercabtagene Zapreleucel
7 Biotech Stocks to Buy for Their Game-Changing Potential
Precision BioSciences: A Strong Buy on Forthcoming Clinical Milestones and Robust Financials
Precision BioSciences: Q2 Earnings Snapshot